Literature DB >> 30480362

CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.

Fan Zhang1, Jia Wang1, Xiaobo Wang2, Nan Wei1, Haiyang Liu1, Xiaoju Zhang1.   

Abstract

INTRODUCTION: Tumours are more likely to metastasize after the development of resistance to EGFR-TKIs. CD146 is a multifunctional molecule and is implicated in tumour invasion and metastasis; however, its role in lung cancer has not been clearly established.
OBJECTIVE: Here, we aimed to explore the relationship between CD146 pathway and stem cell phenotype after EGFR-TKI resistance in lung cancer.
METHODS: EGFR-TKI-resistant cell lines were established by exposing parental cells to erlotinib/gefitinib. The CD146 level was measured by a western blot, RT-PCR and immunocytochemistry fluorescent. Cell migration was examined by the transwell assay and the scratch assay. Stemness phenotype genes were evaluated by RT-PCR and stem cell phenotype was observed by the microsphere formation assay.
RESULTS: CD146 and stemness phenotype genes increased while β-catenin decreased in acquired EGFR-TKI-resistant cell lines. CD146's over-expression induced the up-regulation of stemness-related genes and was inversely correlated with the β-catenin expression, which further increased the migration capability of resistant cancer cells. CD146's knockdown suppressed cell migration and stemness phenotype.
CONCLUSIONS: CD146 molecule contributes to the stemness phenotype and migration in EGFR-TKI-resistant cells. CD146 might be a potential therapeutic target for EGFR-TKI-resistant lung cancer or metastasis prevention.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD146; EGFR-TKI resistance; invasion and metastasis; lung cancer; stemness phenotype

Mesh:

Substances:

Year:  2019        PMID: 30480362     DOI: 10.1111/crj.12976

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  7 in total

1.  Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.

Authors:  Yueling Zhou; Li Wang; Zhen Sun; Jie Zhang; Xiujie Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  PRG2 and AQPEP are misexpressed in fetal membranes in placenta previa and percreta†.

Authors:  Elisa T Zhang; Roberta L Hannibal; Keyla M Badillo Rivera; Janet H T Song; Kelly McGowan; Xiaowei Zhu; Gudrun Meinhardt; Martin Knöfler; Jürgen Pollheimer; Alexander E Urban; Ann K Folkins; Deirdre J Lyell; Julie C Baker
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

3.  Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer.

Authors:  Kazuhisa Kitami; Masato Yoshihara; Yoshihiro Koya; Mai Sugiyama; Shohei Iyoshi; Kaname Uno; Kazumasa Mogi; Sho Tano; Hiroki Fujimoto; Akihiro Nawa; Fumitaka Kikkawa; Hiroaki Kajiyama
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

4.  Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells.

Authors:  Zhirong Jia; Kaiwei Wang; Yalei Duan; Kaiyong Hu; Yameng Zhang; Meisa Wang; Kang Xiao; Shuo Liu; Zhenzhen Pan; Xuansheng Ding
Journal:  Cell Death Discov       Date:  2022-03-18

5.  EMT and Cancer Cell Stemness Associated With Chemotherapeutic Resistance in Esophageal Cancer.

Authors:  Xiaojie Liu; Mingjing He; Linlin Li; Xiya Wang; Shuhua Han; Jinzhu Zhao; Yalong Dong; Mushtaq Ahmad; Leilei Li; Xueyan Zhang; Junfeng Huo; Yunfan Liu; Chengxue Pan; Cong Wang
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

6.  M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR.

Authors:  Fengqi Xiao; Ni Liu; Xinchun Ma; Jing Qin; Yanguo Liu; Xiuwen Wang
Journal:  Thorac Cancer       Date:  2020-09-21       Impact factor: 3.500

7.  CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates.

Authors:  Zheng Lv; Hua-Yi Feng; Wang Tao; Hong-Zhao Li; Xu Zhang
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.